Fate therapeutics highlights positive interim data from its phase 1 study of ft516 in combination with rituximab for b-cell lymphoma at 2021 asco annual meeting

8 of 11 patients in dose escalation cohorts 2 and 3 achieved objective response

FATE Ratings Summary

FATE Quant Ranking